The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Name: MethylphenidateDescription: study to determine doseType: Drug
Description: The maximum plasma concentration achieved after dosing.Measure: Maximum methylphenidate plasma concentration (Cmax), Time: up to 8 Hours
Description: The time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination.Measure: Time to maximum concentration (Tmax) Time: up 8 hours
Description: Area under the plasma concentration-time curve from time zero to the last measurable concentration.Measure: Area under the plasma concentration curve (AUClast) Time: up to 8 hours
Description: Area under the plasma concentration-time curve from time zero to infinity.Measure: Area under the plasma concentration curve (AUCinf) Time: up to 8 hours
Single Group Assignment
There are 2 SNPs
In addition, the study team's in vitro studies have revealed that another common CES1 variant D203E (rs2307227) exhibited significantly impaired activity on MPH metabolism, although the effects on D203E on clinical response are in need of further elucidation.
The first clinically significant CES1 variant G143E (rs71647871), discovered in the study team's lab during the course of a healthy volunteer MPH PK study, led to gross impairments in MPH metabolism.